Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
    1.
    发明授权
    Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base 有权
    依他普仑和包含依他普仑碱的分散片的结晶基

    公开(公告)号:US07834201B2

    公开(公告)日:2010-11-16

    申请号:US11425522

    申请日:2006-06-21

    IPC分类号: C07D307/87

    CPC分类号: C07D307/81

    摘要: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet.

    摘要翻译: 本发明涉及众所周知的抗抑郁药物依他普仑S-1- [3-(二甲基氨基)丙基] -1-(4-氟苯基)-1,3-二氢-5-异苯并呋喃甲腈的结晶碱,所述制剂为 碱,使用碱,草酸盐的纯化盐的制备方法,通过所述方法获得的盐和含有这些盐的制剂的方法,以及制备纯化的依他普仑游离碱或依他普仑的盐的方法, 例如草酸盐,使用氢溴酸盐,通过所述方法获得的盐和含有这些盐的制剂。 最后,本发明涉及硬度至少为22N,口服崩解时间小于120秒的可分散片剂,其包含吸附在水溶性填料上的活性药物成分,其中活性药物成分的熔点为 40-100℃的范围,以及制造这种可分散片剂的方法。

    CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE
    2.
    发明申请
    CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE 审中-公开
    包括ESCITALOPRAM基板的晶圆和可折叠片

    公开(公告)号:US20110046218A1

    公开(公告)日:2011-02-24

    申请号:US12916750

    申请日:2010-11-01

    CPC分类号: C07D307/81

    摘要: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet.

    摘要翻译: 本发明涉及众所周知的抗抑郁药物依他普仑S-1- [3-(二甲基氨基)丙基] -1-(4-氟苯基)-1,3-二氢-5-异苯并呋喃甲腈的结晶碱,所述制剂为 碱,使用碱,草酸盐的纯化盐的制备方法,通过所述方法获得的盐和含有这些盐的制剂的方法,以及制备纯化的依他普仑游离碱或依他普仑的盐的方法, 例如草酸盐,使用氢溴酸盐,通过所述方法获得的盐和含有这些盐的制剂。 最后,本发明涉及硬度至少为22N,口服崩解时间小于120秒的可分散片剂,其包含吸附在水溶性填料上的活性药物成分,其中活性药物成分的熔点为 40-100℃的范围,以及制造这种可分散片剂的方法。

    Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
    4.
    发明授权
    Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base 有权
    依他普仑和包含依他普仑碱的分散片的结晶基

    公开(公告)号:US07560576B2

    公开(公告)日:2009-07-14

    申请号:US12046984

    申请日:2008-03-12

    IPC分类号: C07D307/00 A61K31/34

    CPC分类号: C07D307/81

    摘要: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzo-furancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet.

    摘要翻译: 本发明涉及众所周知的抗抑郁药物依他普仑S-1- [3-(二甲基氨基)丙基] -1-(4-氟苯基)-1,3-二氢-5-异苯并呋喃腈的结晶碱,其制剂 的所述碱的方法,使用碱,通过所述方法获得的盐以及含有这些盐的制剂来制备依他普仑的纯化盐如草酸盐的方法,以及制备纯化的依他普仑游离碱或其盐的方法 使用氢溴酸盐,通过所述方法获得的盐和含有这些盐的制剂,例如草酸盐。 最后,本发明涉及硬度至少为22N,口服崩解时间小于120秒的可分散片剂,其包含吸附在水溶性填料上的活性药物成分,其中活性药物成分的熔点为 40-100℃的范围,以及制造这种可分散片剂的方法。

    CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE

    公开(公告)号:US20080161584A1

    公开(公告)日:2008-07-03

    申请号:US12046999

    申请日:2008-03-12

    IPC分类号: C07D307/87

    CPC分类号: C07D307/81

    摘要: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzo-furancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet.

    Method for the preparation of citalopram
    6.
    发明授权
    Method for the preparation of citalopram 失效
    西酞普兰制备方法

    公开(公告)号:US07271273B2

    公开(公告)日:2007-09-18

    申请号:US11285922

    申请日:2005-11-23

    IPC分类号: C07D307/54

    CPC分类号: C07D307/88

    摘要: The invention provides a new and improved method for the preparation of 5-cyano-phtalid, which is a key intermediate in the preparation of the antidepressant compound citalopram.

    摘要翻译: 本发明提供了一种新的改进的制备5-氰基 - 邻苯二甲酸的方法,该方法是制备抗抑郁化合物西酞普兰的关键中间体。

    Method for the preparation of citalopram

    公开(公告)号:US06420574B1

    公开(公告)日:2002-07-16

    申请号:US09794762

    申请日:2001-02-26

    IPC分类号: C07D30778

    摘要: The present invention relates to a method for the preparation of citalopram comprising reaction a compound of formula (I) with a compound having the formula wherein X is a suitable leaving group and R is —CH2—O—Pg, —CH2—NPg1Pg2, —CO—N(CH3)2, —CH(OR1)(OR2), —C(OR4)(OR5)(OR6), —COOR3, —CH2—CO—NH2, —CH═CHR7 and —CONHR8, wherein Pg is a protection group for an alcohol group, Pg1 and Pg2 are protection groups for an amino group, R1 and R2 are independently selected from alkyl, alkenyl, alkynyl and optionally alkyl substituted aryl or aralkyl groups or R1 and R2 together form a chain of 2 to 4 carbon atoms, each of R3, R4, R5, R6 and R7 are independently selected from alkyl, alkenyl, alkynyl and optionally alkyl substituted aryl or aralkyl and R8 is hydrogen or methyl; to form a compound of the formula wherein R is as defined above; followed by conversion of the R group and isolation of citalopram base or a pharmaceutically acceptable salt thereof.

    METHOD FOR THE PREPARATION OF CITALOPRAM
    8.
    发明申请
    METHOD FOR THE PREPARATION OF CITALOPRAM 审中-公开
    方法制备CITALOPRAM

    公开(公告)号:US20090088469A1

    公开(公告)日:2009-04-02

    申请号:US12329750

    申请日:2008-12-08

    CPC分类号: C07D307/87 C07D307/81

    摘要: Method for the preparation of citalopram comprising reaction of a compound of Formula (IV) wherein R is halogen, or CF3—(CF2)n—SO2—, n being 0 to 8, with a cyanide source in the presence of a palladium catalyst and a catalytic amount of Cu+ or Zn2+, or with Zn(CN)2 in the presence of a palladium catalyst.

    摘要翻译: 制备西酞普兰的方法,其包括其中R为卤素的式(IV)化合物或CF 3 - (CF 2)n -SO 2 - ,n为0至8的化合物与氰化物源在钯催化剂存在下反应, 催化量的Cu +或Zn2 +,或与Zn(CN)2在钯催化剂存在下反应。

    Method for the preparation of citalopram
    10.
    发明授权
    Method for the preparation of citalopram 失效
    西酞普兰制备方法

    公开(公告)号:US06407267B1

    公开(公告)日:2002-06-18

    申请号:US09891874

    申请日:2001-06-25

    IPC分类号: C07D30787

    CPC分类号: C07D307/87

    摘要: A method for the preparation of citalopram comprising reaction of a compound of Formula (IV), wherein R is C1-6 alkyl, acyl, C1-6 alkylsulfonyl or arylsulfonyl, with 3-(N,N-dimethylamino)-propyl magnesium halide, to prepare citalopram.

    摘要翻译: 一种制备西酞普兰的方法,包括其中R为C 1-6烷基,酰基,C 1-6烷基磺酰基或芳基磺酰基的式(Ⅳ)化合物与3-(N,N-二甲基氨基) - 丙基卤化镁反应, 准备西酞普兰。